In this study, we investigated the mutation profiles of HER2-positive breast cancer patients in China and analyzed the mutation differences between primary HER2-positive breast cancers with pCR and non-pCR after HER2-targeted NACT. Here, ERBB2 is linked to breast carcinoma.